NIH-funded research NIH-funded research

Effects of a medication on brain function and thinking skills in veterans with schizophrenia

Official title: GLP-1 Receptor Agonist Effects on Neuronal Function and Cognition in Veterans with Schizophrenia

Funded at VA Eastern Colorado Health Care System · NIH-11054481 · Data updated 2026-11-12

This study is looking at how a medication called a GLP-1 receptor agonist might help improve thinking and brain function in veterans with schizophrenia, using special imaging to see how it affects their brain activity.

More Schizophrenia research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionVA Eastern Colorado Health Care System
NIH-funded
Lab location1 site (Aurora, UNITED STATES)
Project startApril 1, 2025
Project endMarch 31, 2029
Funding year2025
NIH project number1I01CX002834-01A1
Project IDNIH-11054481 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are veterans diagnosed with schizophrenia who experience cognitive difficulties.

Less likely to help

Patients without a diagnosis of schizophrenia or those who do not experience cognitive deficits may not benefit from this research.

What this research studies

This research investigates how a specific medication, known as a GLP-1 receptor agonist, can improve brain function and cognitive abilities in veterans diagnosed with schizophrenia. The study focuses on understanding the relationship between brain activity, particularly in the hippocampus, and cognitive deficits that affect daily life. By using advanced imaging techniques, researchers aim to identify changes in brain function that correlate with improvements in thinking skills. The ultimate goal is to develop effective treatments that enhance cognitive performance in this population.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that significantly improve cognitive function and quality of life for veterans with schizophrenia.

How similar studies have gone: Previous research has shown promise in targeting cognitive deficits in schizophrenia, but this specific approach using GLP-1 receptor agonists is relatively novel.

Where this research is happening

  • VA Eastern Colorado Health Care System
    Aurora, United States
    Active

Researchers

  • Principal investigator: Tregellas, Jason R — VA Eastern Colorado Health Care System
  • Study coordinator: Tregellas, Jason R

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.